Kornimate/medical-research-clean huggingface dataset:
effect of neurodynamic exercises and education program applied with virtual reality assisted telerehabilitation method in conservative treatment of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome; Peripheral Neuropathy; Median Nerve Entrapment

Summary: the aim in this prospective, randomized and controlled, single-blind study; in the conservative treatment of patients diagnosed with carpal tunnel syndrome, to investigate the effects of neurodynamic exercises that applied with nonimmersive virtual reality technology and patient education program presented by the telerehabilitation method on pain-numbness, functional status and quality of life, to compare the effects of neurodynamic exercises that applied with traditional methods and standard education given to patients in outpatient clinic conditions on the same parameters.


Eligibility criteria:
inclusion criteria: * 18-65 years * being diagnosed with cts clinically and electrophysiologically exclusion criteria: * \ 65 years * distal motor latency \> 6.0 msn. * thenar atrophy * surgery history for cts * steroid injection for cts * physical treatment for cts in the last 6 months * cervical radiculopathy * tenosynovitis * peripheral polyneuropathy * another compressive neuropathy in the ipsilateral upper extremity * history of trauma/fracture to the hand-wrist region * pregnancy * metabolic disease * rheumatic/autoimmune disease * kidney failure * lack of internet access * not having the equipment to make video calls at home

Keywords: carpal tunnel syndrome virtual reality telerehabilitation exercise education ergonomics
histamine as a molecular transducer of adaptation to exercise

Conditions: Postexercise Hypotension

Summary: this study is investigating the role of histamine in generating adaptation to exercise

exercise promotes and maintains healthy cardiovascular, musculoskeletal, and metabolic function, but the signals and mechanisms which transduce these effects are poorly understood. histamine plays a role in some of the positive benefits of exercise. the goal of this study is to determine the factors that regulate exercise's effects on endothelial and vascular function, with a focus on histamine released from mast cells in skeletal muscle. participants will perform exercise or participate in interventions like heating that may replicate some of the effects of exercise. during most experiments, investigators will insert an intravenous catheter in an arm vein and microdialysis probes in the leg, collect dialysate from the microdialysis probe and blood from the vein, record noninvasive measures, and have the participants perform exercise or undergo heating.

Eligibility criteria:
inclusion criteria: * age 18 -40 exclusion criteria: * systolic ≥ 120 * diastolic ≥ 80 * body mass index (bmi) ˃ 28 kg/m2 * prior diagnosis of cardiovascular disease, diabetes, autonomic disorders, or asthma * smoking or nicotine use * ongoing medical therapy (other than birth control) * ongoing use of over-the-counter or prescription antihistamines * allergies or hypersensitivities to drugs, local anesthetics, skin disinfectants, adhesives, or latex * pregnant, breastfeeding subjects, or planning to become pregnant in the next 12 months * mobility restrictions that interfere with physical activity * high physical activity based on international physical activity questionaire (ipaq1) * non-english speaking

Keywords: histamine mast cell exercise
efficacy of secukinumab compared to ustekinumab in adults with active psoriatic arthritis and failure of tnfα-inhibitor treatment

Conditions: Psoriatic Arthritis

Summary: the purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous tnfα-inhibitor treatment


Eligibility criteria:
key inclusion criteria: * diagnosis of psa as classified by caspar criteria for at least 6 months before randomization. * active psa at baseline defined as ≥ 3 tender joints out of 68 and ≥ 3 swollen joints out of 66 (dactylitis of a digit counts as one joint each). * inadequate response or intolerance to previous or current treatment with at least one tnfα inhibitor * inadequate response or intolerance to conventional disease modifying anti-rheumatic drugs (cdmards) * diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥ 2 cm diameter and/or nail changes consistent with psoriasis and/or documented history of plaque psoriasis. * rheumatoid factor (rf) and anti-cyclic citrullinated peptide (ccp) antibodies negative at screening. key exclusion criteria: * pregnant or nursing women, * previous exposure to secukinumab, ustekinumab or any other biologic drug directly targeting il-17, il-17 receptor, il-12 or il-23. * patients for whom the use of secukinumab or ustekinumab is contraindicated. * use of any other investigational drug. previous treatment with any cell-depleting therapies including but not limited to anti-cd20 or investigational agents * evidence of ongoing infectious or malignant process * subjects receiving high potency opioid analgesics * ongoing use of prohibited psoriasis treatments/medications other protocol-defined inclusion/exclusion criteria may apply

Keywords: psoriatic arthritis psoriasis arthropathica psoriatic arthropathy
alpha lipoic acid and polycystic ovary syndrome

Conditions: Insulin Resistance; Oxidative Stress

Summary: the study will recruit 40 subjects with polycystic ovary syndrome (pcos) as defined by the nih criteria. the subjects will be pre-screened for insulin sensitivity using fasting insulin and glucose levels and oral glucose tolerance test. the 20 most insulin resistant subjects will undergo measurements of in vivo insulin action by hyperinsulinemic, euglycemic clamp. body composition will be measured by dual-energy x-ray absorptiometry (dexa). plasma lipids and markers of oxidative stress will be measured. they will then receive open label controlled release alpha lipoic acid (crla) at 800 mg twice daily for 16 weeks. after treatment hyperinsulinemic euglycemic clamps, dexa, plasma lipids and markers of oxidative stress will be repeated. hypotheses: la will improve insulin sensitivity in pcos subjects; la will reduce oxidative stress, testosterone levels and improve cardiovascular risk factors.

insulin resistance commonly occurs in patients with polycystic ovary syndrome (pcos) and may be responsible for many of the long term complications of pcos. patients with pcos are at increased risk for developing type 2 diabetes and the metabolic syndrome (hypertension, dyslipidemia and cardiovascular disease). data suggest that oxidative stress contributes to insulin resistance and thus inhibitors of oxidative stress improve insulin action. alpha lipoic acid (la) is synthesized in the liver and other tissues and is a key component of several mitochondrial enzyme complexes responsible for oxidative glucose metabolism and cellular energy production. when used pharmacologically, la functions as a safe and effective antioxidant, recycling vitamins c and e,elevating glutathione levels,and lowering reactive oxygen species. cell culture studies reveal that la reverses the effects of oxidative stress and improving insulin action. preliminary clinical data indicate that antioxidants may improve insulin resistance in pcos patients. we propose, therefore, to study la's effects on insulin-stimulated glucose uptake (insulin clamp) in a well characterized population of insulin resistant pcos patients. because these patients usually present in the adolescent and teenage years, the development of safe, long-term, treatment strategies are needed.

Eligibility criteria:
inclusion criteria: * pcos diagnosis * 18 years of age or older * body mass index below 35 * willing to use any form of contraception for the duration of the study exclusion criteria: * diabetes * pregnancy * liver or heart disease or other health problems * taking medications that affect insulin resistance

Keywords: pcos polycystic ovary syndrome polycystic ovarian syndrome alpha lipoic acid insulin resistance oxidative stress
adding mgso4 to epidural levobupivacaine in cs for patients with preeclampsia

Conditions: Preeclampsia

Summary: this study aims at evaluating the effect of adding magnesium sulphate epidurally as an adjunct to levobupivacaine on the quality of anesthesia and perioperative pain relief in patients with preeclampsia undergoing elective caesarian section (cs).

pregnant women with preeclampsia undergoing elective cs in will be included in the study. all patients participating in the study will be randomly divided into two groups; magnesium sulphate group (study group) and placebo group (control group). patients in the study group will receive epidural 20 ml levobupivacaine hydrochloride 0.5% plus 5 ml magnesium sulphate 10% (500 mg) while patients in the control group will received epidural 20 ml levobupivacaine hydrochloride 0.5% plus 5 ml saline 0.9%.

Eligibility criteria:
inclusion criteria: * pregnant women with preeclampsia undergoing elective cs. exclusion criteria: * age \ 35 years. * height \ 180 cm. * body mass index (bmi) \> 35 kg/m2. * active labor. * multifetal pregnancy. * fetal distress. * medical conditions complicating pregnancy. * hellp syndrome. * thrombocytopenia. * hepatic or renal impairment. * pulmonary edema or cyanosis. * placenta previa. * vaginal bleeding or placental abruption. * contraindication for central neuraxial block. * history of adverse reaction to any study medication. * history of analgesic use. * magnesium therapy. * chronic pain syndrome. * presence of communication difficulties preventing reliable assessment. * refusal to undergo regional anesthesia.

Keywords: levobupivacaine magnesium preeclampsia epidural
long-term follow-up of participants dosed with an investigational gene editing therapy for cardiovascular disease

Conditions: Atherosclerotic Cardiovascular Disease; Heterozygous Familial Hypercholesterolemia; Hypercholesterolemia

Summary: ltf-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.


Eligibility criteria:
inclusion criteria 1. a participant has completed or discontinued from a verve sponsored clinical study in which they received at least one dose of study drug. 2. a participant has provided informed consent for ltf-001. exclusion criteria: n/a

Keywords: ltf-001 cardiovascular disease gene editing familial hypercholesterolemia base editing
symptom preoccupation in atrial fibrillation (af) and its role in af-related disability

Conditions: Atrial Fibrillation

Summary: a cross-sectional study (n=400) will investigate the prevalence of symptom preoccupation and its role in af-related disability. subjectively-rated assessments will be gathered from 400 af patients.

in the present study we aim to investigate symptom preoccupation in patients with atrial fibrillation (af) to further improve the understanding of the role of psychological factors in af-related disability. a cross-sectional study (n=400) will investigate the prevalence of symptom preoccupation and its role in af-related disability. subjectively-rated assessments will be gathered from 400 af patients.

Eligibility criteria:
inclusion criteria: * 18 years of age * diagnoses with af * able to read swedish and access to computer exclusion criteria: -

Keywords: symptom preoccupation atrial fibrillation quality of life cardiac anxiety
the effects of sacubitril/valsartan on cardiac oxygen consumption and efficiency of cardiac work in heart failure patients

Conditions: Heart Failure

Summary: this is a phase iv, prospective, randomized, double-blind, double-dummy, parallel-group study. the study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the efficiency of cardiac work in patients with nyha ii-iii heart failure (hf) and reduced systolic function using 11c-acetate positron emission tomography (pet) and echocardiography.

subjects were randomized into valsartan or sacubitril/valsartan arms in a 1:1 ratio. regardless of the treatment arm a subject is in, the study drug was up-titrated to the highest tolerated dose level during the scheduled study visits. the different strengths of the two study drugs were not identical in appearance so the possible dose modification(s) during the treatment period could not be performed in a blinded manner. subjects started on valsartan 80 mg bid or sacubitril/valsartan 100 mg bid dose and there was only one scheduled up-titration visit after the randomization. exception for this were the subjects that were on valsartan 160 mg bid dose during the run-in phase. these subjects were randomized directly to valsartan 160 mg bid or sacubitril/valsartan 100 mg bid. subjects that were randomized to valsartan arm had similar visit after which they continued on the same dose. for subjects that were randomized from valsartan 160 mg bid to sacubitril/valsartan 100 mg bid the dose was up-titrated to 200 mg bid if clinically possible. the total duration for each patient was planned to be about 14 weeks but could be longer if required for scheduling purposes . the longest participation, from signing of icf until end of study, was 26 weeks.

Eligibility criteria:
inclusion criteria: * 40-80 years of age * chronic hf with reduced ef (left ventricle ef 25-35%) and nyha class ii-iii symptoms. * systolic bp 110-160 mm hg * optimal standard hf therapy according to european society of cardiology (esc) guidelines at a stable dose for at least 4 weeks before the screening visit. exclusion criteria: * estimated glomerular filtration rate (egfr) \< 45 ml/min * serum potassium \> 5.2 mmol/l and creatinine \>1.5 x uln

Keywords: heart failure with reduced left ventricular ejection fraction lvef cardiac dysfunction heart muscle dysfunction left ventricular (lv) dilation left ventricular hypertrophy hf ahf chf ccf acute heart failure chronic heart failure congestive heart failure congestive cardiac failure
combined intensive and conventional exercise on nonalcoholic fatty liver disease (nafld)

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD)

Summary: the prevalence of nafld is 50-70% in obese people. a decrease of calorie intake and increase of physical activity are recommended as an effective approach for the prevention and treatment of nafld. however, the exercise model for nafld intervention is understudied. in the present study we aim to compare the effect of intensive and conventional exercise interventions on nafld.


Eligibility criteria:
1. subjects with nafld determined by mrs ; 2. age 40-65 years old; 3. waist circumference\> 90cm for men and \> 85cm for women.

Keywords: nafld exercise hepatic triglycerides
hepato-pancreato-biliary abnormalities in fibrous dysplasia of bone/mccune albright syndrome

Conditions: Fibrous Dysplasia of Bone

Summary: fibrous dysplasia of bone /mccune albright syndrome (fd/mas) is a rare bone disease caused by somatic mutations in gnas gene. this gnas mutation predisposes to cancers, including breast cancer, thyroid cancer, chondrosarcoma and osteosarcoma, as well as biliary tract anomalies, liver-tumors or pancreatic tumors - ipmns. intraductal papillary and mucinous neoplasms of the pancreas (ipmn) are cystic intraepithelial ductal lesions developed at the expense of pancreatic ducts. they are pre-cancerous lesions, requiring monitoring and, in case of progression or malignant degeneration, surgical resection. pancreatic mri screening of patients with polyostotic fd and mas is recommended. the aim of this study is to investigate the epidemiology and characteristics of these hepato-pancreato-biliary abnormalities (prevalence, age of onset, degeneration), based on magnetic resonance imaging (mri) realized during the follow-up of patients with fd/mas treated in a french fd expert center. a better understanding of these ipmns and other digestive abnormalities will enable clinicians to improve the management and monitoring in this high-risk population.


Eligibility criteria:
inclusion criteria: * adults ≥18 years with polyostotic fd/mas * followed up in the national fd reference center (lyon) or in a fd french expert center: angers, bordeaux, brest, caen, clermont-ferrand, lille, marseille, montpellier, nice, paris, poitiers, rennes, saint-etienne, strasbourg. * who had an hepato-bilio-pancreatic mri during their follow-up, since january 2002 * no objection to data collection exclusion criteria: -opposition to data collection

Keywords: fibrous dysplasia of bone mccune albright syndrome pancreatic neoplasms ipmn
study of chemotherapy plus icotinib to treat egfr mutation-positive non-small-cell lung cancer

Conditions: NSCLC

Summary: non-small-cell lung cancer (nsclc) patients with activating epidermal growth factor receptor (egfr) mutations are exquisitely sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (egfr-tkis) which is widely used in advanced patients. whether treatment with egfr-tkis improves outcomes in patients with resected nsclc harboring egfr mutations is still under investigated. this study aims to observe and compare the efficacy and safety of intercalated combination of chemotherapy plus icotinib in patients undergoing resection of egrf mutation-positive non-small cell lung cancer stagingⅰb (with high risk factor) to ⅲa.


Eligibility criteria:
inclusion criteria: * patients undergoing completely resection of egrf mutation-positive nsclc * staging ⅰb (with high risk factor) to ⅲa * ps\<2 * adequate hematological, biochemical and organ functions. exclusion criteria: * systemic anticancer therapy prior to surgery, other malignancies before or during the study, any unstable illness, women who were pregnant or lactating.

Keywords: egfr tyrosine kinase inhibitor
a study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes


Eligibility criteria:
inclusion criteria: * type 2 diabetes * bmi 20-45kg/m2 inclusive exclusion criteria: * females who are pregnant, lactating, or less than 6 weeks post-partum * current symptomatic heart failure (nyha class ii-iv)

Keywords: diabetes
a comparison of the therapeutic effect between head-point acupuncture and conventional body acupuncture on insomnia

Conditions: Sleep Initiation and Maintenance Disorders

Summary: the investigators will conduct a single-center, and randomized controlled cases study. a total of 120 participants with insomnia will be enrolled. the aim of the study is to compare the therapeutic effect between head-acupoints acupuncture and body-acupoints acupuncture on insomnia.

the investigators will conduct a single-center, and randomized controlled cases study. a total of 120 participants with insomnia will be enrolled, and randomly assigned into two groups, 60 of them are the head-acupoints acupuncture group, who will receive gv20, ex-hn-1, gv21, gv22, gv23, gv24, gv29, and bilateral gb13 head-acupoints acupuncture treatment, and 60 of them are the body-acupoints acupuncture group, who will receive bilateral ht7, pc6, sp6, st36, ki3, lr3 body-acupoints acupuncture treatment for 4 weeks. the primary outcomes of therapeutic effect on insomnia are changes of the pittsburgh sleep quality index (psqi), epworth sleepiness scale (ess), and the hospital anxiety and depression scale (hads).the time frame of the three primary outcomes are: baseline week 0, week 2, week 4 and week 6. the secondary outcomes of therapeutic effect on insomnia are sleep parameters including sleep efficiency (se), sleep awakenings (sa) and total sleep time (tst) recorded by the actigraphy (time frame: baseline week 0, week 2, week 4 and week 6), as well as the heart rate viability(hrv) recorded by the ecg monitor (time frame: baseline week 0, week1, week 2, week 3, week 4 and week 6; and 30 minutes before and 60 minutes after acupuncture through study completion).

Eligibility criteria:
inclusion criteria: 1. aged 20\~70 years, 2. met the diagnostic criteria of insomnia according to the diagnostic and statistical manual of mental disorders (fifth edition, dsm-v) 3. experienced insomnia at least three times a week for more than a month 4. voluntarily agreed with the investigation and signed a written informed con- sent form before the clinical trial started. exclusion criteria: 1. a pregnant or lactating woman 2. the patient's insomnia is caused by mental disorders other than mild anxiety, 3. the patient has serious cardiovascular, liver, kidney or hematopoietic system disease 4. the patient's insomnia is caused by nervous system disease (eg, stroke, parkinson's disease) 5. the patient has taken chinese herbs and herbal formulas for insomnia two weeks before the trial 6. the patient with cardiac pacemaker 7. the patient does not want to wear portable physiological signal recording device (somnowatchtm) and handheld ecg monitor 8. the patient has a history of sleep apnea

Keywords: acupuncture primary insomnia
ten-year outcomes of pre-combat trial

Conditions: Coronary Artery Disease

Summary: this study evaluates ten-year outcomes of premier of randomized comparison of sirolimus-eluting stent implantation versus coronary artery bypass surgery for unprotected left main coronary artery stenosis(precombat trial).

this study is an extended one of precombat trial.

Eligibility criteria:
inclusion criteria: * subject group enrolled in precombat trial

Keywords: pci cabg left main
compare s-1 plus oxaliplatin to s-1 as adjuvant chemotherapy after d2 resection in patients with gastric cancer

Conditions: Gastric Cancer

Summary: background: it is shown that ts-1 as adjuvant chemotherapy after d2 resection in patients with gastric cancer can improve dfs and os in one japanese trial. and ts-1 has become one of the standard therapies to these patients. but it is still unknown whether it would improve more to os and dfs than single ts-1 after combined with oxaliplatin . this trial is designed to investigate the efficacy and safety of ts-1 plus oxaliplatin versus ts-1 single as adjuvant chemotherapy after d2 resection in patients with gastric cancer. patients and methods: in this study , patients with histologically confirmed gastric cancer who received d2 resection and staged ii or iii, aged from 18 to 70 years and with eastern cooperative oncology group performance status ≤2 and adequate organ function, are randomized 1:1 to oxaliplatin 100mg/m2 on day 1 and ts-1 40\~60mg twice everyday for 14 days in a 21-days cycle for total 6 cycles followed by ts-1 single with the same dose and frequency to the end of the 1st year postoperatively(sox) , or ts-1 single 40\~60mg twice everyday for 14 days in a 21-days cycle to the end of the 1st year postoperatively (ts-1). the primary end point is overall survival (os), and secondary end point is disease free survival(dfs) and safety. final study analysis will be conducted in the end of the 5th year after the last patient's enrollment.


Eligibility criteria:
inclusion criteria: * informed consensus of patients * be able to receive oral administration * from 18 to 70 years old * be proven to be primary adenocarcinoma of gastric cancer and staged ii or iii by pathological evidences * without other chemotherapy and/or radiation against to the disease * normal function of other organs including heart,liver ,kidney and so on * eastern cooperative oncology group performance status:0\~2 exclusion criteria: * history of other malignancy * allergic reaction to s-1 or oxaliplatin * be enrolling in other clinical trials * abnormal gi tract function * dysfunction of other organs * female in pregnancy or lactation,or refuse to receive contraception measures during chemotherapy * other situation to be judged not adaptive to the study by investigators

Keywords: gastric cancer chemotherapy d2 resection s-1